[酒渣鼻患者小肠细菌过度生长的患病率和风险：一项系统综述和荟萃分析]。

IF 0.3 4区医学 Q3 MEDICINE, GENERAL & INTERNAL

Terapevticheskii Arkhiv Pub Date : 2025-07-31 DOI:10.26442/00403660.2025.07.203297

А R Khurmatullina, Y A Kucheryavyy, D N Andreev, O B Tamrazova, I V Maev

{"title":"[酒渣鼻患者小肠细菌过度生长的患病率和风险：一项系统综述和荟萃分析]。","authors":"А R Khurmatullina, Y A Kucheryavyy, D N Andreev, O B Tamrazova, I V Maev","doi":"10.26442/00403660.2025.07.203297","DOIUrl":null,"url":null,"abstract":"Aim: To systematize data on the prevalence and risk of small intestinal bacterial overgrowth (SIBO) in patients with rosacea.Materials and methods: The search for studies was conducted in the MEDLINE/PubMed, EMBASE, and the Russian Science Citation Index from January 1, 1985, to April 5, 2025. The inclusion criteria were original clinical studies in English or Russian with detailed descriptive statistics describing the prevalence of SIBO in adults with rosacea. The analysis included an assessment of the SIBO prevalence, calculation of relative risk, and 95% confidence interval (CI) using a random effects model. Heterogeneity was assessed using I²-statistics, and publication bias was examined with funnel plots and Begg-Mazumdar and Egger tests.Results: The meta-analysis included 6 studies with 801 subjects (581 subjects with rosacea, 220 controls). The overall prevalence of SIBO in patients with rosacea was 35.8% (95% CI 23.626-48.985) compared to 9.391% (95% CI 4.256-16.265) in controls. The risk of developing SIBO in patients with rosacea was 3.501 times higher (relative risk 3.50; 95% CI 1.347-9.100; p=0.012). Treatment with rifaximin (1200 mg/day for 10 days) resulted in significant improvement or remission of rosacea in 57.9% (95% CI 49.5-66.3) of patients, with the highest effectiveness (up to 85.7%) observed in those with successful eradication of SIBO.Conclusion: The results of a systematic review and meta-analysis confirm the potential association between SIBO and rosacea and demonstrate the effectiveness of rifaximin in treating cutaneous manifestations of rosacea in these patients. It is necessary to consider SIBO diagnosis when assessing patients with rosacea, especially in resistant forms of the disease.","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"97 7","pages":"580-586"},"PeriodicalIF":0.3000,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Prevalence and risk of small intestinal bacterial overgrowth in patients with rosacea: A systematic review and meta-analysis].\",\"authors\":\"А R Khurmatullina, Y A Kucheryavyy, D N Andreev, O B Tamrazova, I V Maev\",\"doi\":\"10.26442/00403660.2025.07.203297\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Aim: To systematize data on the prevalence and risk of small intestinal bacterial overgrowth (SIBO) in patients with rosacea.Materials and methods: The search for studies was conducted in the MEDLINE/PubMed, EMBASE, and the Russian Science Citation Index from January 1, 1985, to April 5, 2025. The inclusion criteria were original clinical studies in English or Russian with detailed descriptive statistics describing the prevalence of SIBO in adults with rosacea. The analysis included an assessment of the SIBO prevalence, calculation of relative risk, and 95% confidence interval (CI) using a random effects model. Heterogeneity was assessed using I²-statistics, and publication bias was examined with funnel plots and Begg-Mazumdar and Egger tests.Results: The meta-analysis included 6 studies with 801 subjects (581 subjects with rosacea, 220 controls). The overall prevalence of SIBO in patients with rosacea was 35.8% (95% CI 23.626-48.985) compared to 9.391% (95% CI 4.256-16.265) in controls. The risk of developing SIBO in patients with rosacea was 3.501 times higher (relative risk 3.50; 95% CI 1.347-9.100; p=0.012). Treatment with rifaximin (1200 mg/day for 10 days) resulted in significant improvement or remission of rosacea in 57.9% (95% CI 49.5-66.3) of patients, with the highest effectiveness (up to 85.7%) observed in those with successful eradication of SIBO.Conclusion: The results of a systematic review and meta-analysis confirm the potential association between SIBO and rosacea and demonstrate the effectiveness of rifaximin in treating cutaneous manifestations of rosacea in these patients. It is necessary to consider SIBO diagnosis when assessing patients with rosacea, especially in resistant forms of the disease.\",\"PeriodicalId\":22209,\"journal\":{\"name\":\"Terapevticheskii Arkhiv\",\"volume\":\"97 7\",\"pages\":\"580-586\"},\"PeriodicalIF\":0.3000,\"publicationDate\":\"2025-07-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Terapevticheskii Arkhiv\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.26442/00403660.2025.07.203297\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Terapevticheskii Arkhiv","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.26442/00403660.2025.07.203297","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

摘要

目的：对酒渣鼻患者小肠细菌过度生长（SIBO）的患病率和风险进行系统化分析。材料和方法：从1985年1月1日至2025年4月5日，在MEDLINE/PubMed、EMBASE和俄罗斯科学引文索引中进行研究检索。纳入标准为英文或俄文的原始临床研究，并附有描述成人酒渣鼻SIBO患病率的详细描述性统计数据。分析包括SIBO患病率评估、相对风险计算和使用随机效应模型的95%置信区间（CI）。异质性采用I²统计量评估，发表偏倚采用漏斗图和Begg-Mazumdar和Egger检验。结果：meta分析纳入6项研究，共801名受试者（581名酒渣鼻患者，220名对照组）。酒渣鼻患者SIBO的总体患病率为35.8% (95% CI 23.626-48.985)，而对照组为9.391% （95% CI 4.256-16.265）。酒渣鼻患者发生SIBO的风险是前者的3.501倍(相对风险3.50；95% ci 1.347-9.100；p = 0.012)。利福昔明治疗（1200mg /天，持续10天）导致57.9% （95% CI 49.5-66.3）患者酒渣鼻的显著改善或缓解，在成功根除SIBO的患者中观察到最高的有效性（高达85.7%）。结论：一项系统综述和荟萃分析的结果证实了SIBO与酒渣鼻之间的潜在关联，并证明了利福昔明治疗这些患者酒渣鼻皮肤表现的有效性。有必要考虑SIBO诊断时，评估患者的酒渣鼻，特别是在抵抗形式的疾病。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

[Prevalence and risk of small intestinal bacterial overgrowth in patients with rosacea: A systematic review and meta-analysis].

Aim: To systematize data on the prevalence and risk of small intestinal bacterial overgrowth (SIBO) in patients with rosacea.

Materials and methods: The search for studies was conducted in the MEDLINE/PubMed, EMBASE, and the Russian Science Citation Index from January 1, 1985, to April 5, 2025. The inclusion criteria were original clinical studies in English or Russian with detailed descriptive statistics describing the prevalence of SIBO in adults with rosacea. The analysis included an assessment of the SIBO prevalence, calculation of relative risk, and 95% confidence interval (CI) using a random effects model. Heterogeneity was assessed using I²-statistics, and publication bias was examined with funnel plots and Begg-Mazumdar and Egger tests.

Results: The meta-analysis included 6 studies with 801 subjects (581 subjects with rosacea, 220 controls). The overall prevalence of SIBO in patients with rosacea was 35.8% (95% CI 23.626-48.985) compared to 9.391% (95% CI 4.256-16.265) in controls. The risk of developing SIBO in patients with rosacea was 3.501 times higher (relative risk 3.50; 95% CI 1.347-9.100; p=0.012). Treatment with rifaximin (1200 mg/day for 10 days) resulted in significant improvement or remission of rosacea in 57.9% (95% CI 49.5-66.3) of patients, with the highest effectiveness (up to 85.7%) observed in those with successful eradication of SIBO.

Conclusion: The results of a systematic review and meta-analysis confirm the potential association between SIBO and rosacea and demonstrate the effectiveness of rifaximin in treating cutaneous manifestations of rosacea in these patients. It is necessary to consider SIBO diagnosis when assessing patients with rosacea, especially in resistant forms of the disease.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Terapevticheskii Arkhiv 医学-医学：内科

CiteScore

1.40

自引率

33.30%

发文量

171

审稿时长

3-8 weeks

期刊介绍： Терапевтический архив The journal was founded by the prominent Russian therapists M.P. Konchalovsky and G.F. Lang in 1923. Then its editors-in-chief were Professors V.N. Vinogradov and A.G. Gukasyan. Since 1972, E.I. Chazov, Academician of the Russian Academy of Sciences, has been heading the editorial board of the journal. Over 90 years, there have been more than 1000 issues where the authors and editorial staff have done their best for readers to keep abreast of current advances in medical science and practice and for physicians to master the advanced principles of recognition and treatment of a wide spectrum of visceral diseases. The papers published in the journal (editorials, original articles, lectures, reviews, etc.) cover both current scientific achievements and practical experience in diagnosing, treating, and preventing visceral diseases. The authors of publications are not only Russian, but also foreign scientists and physicians. All papers are peer-reviewed by highly qualified Russian specialists. The journal is published monthly. Traditionally, each issue has predominantly certain thematic areas covering individual therapy specializations. Every year, one of the issues is devoted to related problems in practical medicine (allergology and immunology, neurology and psychiatry, obstetrics, oncology, etc.). This all draws the attention of the reading public to the journal. The journal is indexed in RSCI (Russian Science Citation Index), PubMed/Medline, Index Medicus, Scopus/EMBASE, Web of Science Core Collection (Science Citation Index Expanded), Web of Science (Russian Science Citation Index - RSCI, Current Contents Connect, BIOSIS Previews), Google Scholar, Ulrich''s Periodicals Directory. The journal is included in the list of periodicals recommended by the Higher Attestation Committee for publishing the papers containing the basic materials of doctoral and candidate dissertations. By the decision of the Presidium of the Russian Academy of Medical Sciences, the “Therapevticheskiy Arkhiv” was awarded the Botkin medal. It was admitted to the European Association of Sciences Editors (EASE). The journal was honored with the Golden Press Fund decoration at the 13th International Press Professional Exhibition.